Guides

How do tirzepatide and semaglutide differ at GIP and GLP-1 receptors?

Short answer

Tirzepatide activates both GIP and GLP-1 receptors. Semaglutide is a GLP-1 receptor agonist. Counting receptor types describes a mechanism. It cannot predict how an individual’s weight will change.12

What is an agonist?

An agonist activates a receptor and triggers a signal. GIP and GLP-1 are hormones made by the body. Their signals help regulate blood glucose, and GLP-1 signalling also plays a role in appetite.12

Does that mean two drugs in a tirzepatide pen?

One active molecule can interact with both receptor types. A structural study examined how the same molecule binds to each. A receptor model by itself cannot tell an individual what side effects they will experience.3

How can I check a weight comparison?

The SURMOUNT-5 registry entry specifies change in body weight at 72 weeks as the primary outcome. That gives the group comparison a measurable target. Also look at who could take part and which adverse events were recorded.4

Primary sources

  1. EMA, European public assessment report for Mounjaro
  2. EMA, European public assessment report for Wegovy
  3. Primary structural study of tirzepatide at two receptors (2022)
  4. Trial registry, SURMOUNT-5 and its prespecified outcomes
Cite this page

Fastzuleicht · Editorial team. How do tirzepatide and semaglutide differ at GIP and GLP-1 receptors? (19 November 2026). https://fastzuleicht.de/guides/gip-glp1-tirzepatide-semaglutide-receptors/